Browse the corpus

REFERENCES Abbas R, Hug BA, Leister C, et al, “A Phase I Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Bosutinib (SKI-606) in Healthy Adult Subjects,” Cancer Chemother Pharmacol , 2012, 69(1):221-7. [PubMed 21691746 ] Abbas R, Hug BA, Leister C, et al, “A Randomized, Crossover, Placebo- and Moxifloxacin-Controlled Study to Evaluate the Effects of Bosutinib (SKI-606), A Dual Src/Abl Tyrosine Kinase Inhibitor, on Cardiac Repolarization in Healthy Adult Subjects,” Int J Cancer , 2012, 131(3):E304-11. [PubMed 22065400 ] Abbas R, Hug BA, Leister C, et al, “Effect of Ketoconazole on the Pharmacokinetics of Oral Bosutinib in Healthy Subjects,” J Clin Pharmacol , 2011, 51(12):1721-7. [PubMed 21148045 ] Cortes JE, Kantarjian HM, Brümmendorf TH, et al, “Safety and Efficacy of Bosutinib (SKI-606) in Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Imatinib,” Blood , 2011, 118(17):4567-76. [PubMed 21865346 ] Cortes JE, Kim DW, Kantarjian HM, et al, “Bosutinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial,” J Clin Oncol , 2012, 30(28):3486-92. [PubMed 22949154 ] Khoury HJ, Cortes JE, Kantarjian HM, et al, “Bosutinib is Active in Chronic Phase Chronic Myeloid Leukemia After Imatinib and Dasatinib and/or Nilotinib Therapy Failure,” Blood , 2012, 119(15):3403-12. [PubMed 22371878 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Redaelli S, Piazza R, Rostagno R, et al, “Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants,” J Clin Oncol , 2009, 27(3):469-71. [PubMed 19075254 ] Remsing Rix LL, Rix U, Colinge J, et al, “Global Target Profile of the Kinase Inhibitor Bosutinib in Primary Chronic Myeloid Leukemia Cells,” Leukemia , 2009, 23(3):477-85. [PubMed 19039322 ] Trask PC, Cella D, Besson N, et al, “Health-Related Quality of Life of Bosutinib (SKI-606) in Imatinib-Resistant or Imatinib-Intolerant Chronic Phase Chronic Myeloid Leukemia,” Leuk Res , 2012, 36(4):438-42. [PubMed 22036634 ] Topic 86371 Version 12.0

Remsing Rix LL, Rix U, Colinge J, et al, “Global Target Profile of the Kinase Inhibitor Bosutinib in Primary Chronic Myeloid Leukemia Cells,” Leukemia , 2009, 23(3):477-85. [PubMed 19039322 ] Trask PC, Cella D, Besson N, et al, “Health-Related Quality of Life of Bosutinib (SKI-606) in Imatinib-Resistant or Imatinib-Intolerant Chronic Phase Chronic Myeloid Leukemia,” Leuk Res , 2012, 36(4):438-42. [PubMed 22036634 ] Topic 86371 Version 12.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]